Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q1 2024 U.S. Biopharma Recap

Biopharma’s rebound came into full effect in Q1 2024. Major biopharma indices extended their year-end rally helping lay the foundation for an extremely active quarter for public financings with 105 total offerings (including IPOs, follow-ons, PIPEs and RDs), raising a total of $18.7 billion. Both totals were the highest since the first quarter of 2021. Additionally, the private financing market skewed later-stage and “crossovers” became more common thanks to a reopening IPO window.

Meanwhile, big pharma’s appetite for deal making continued with eight acquisitions announced over $1 billion in deal value and 10 partnering deals announced with more than $50 million in upfront proceeds this quarter. Although, some market participants worry the recovery has been too swift, and the U.S. presidential election looms large for overall market health, the stage remains set for a much more favorable 2024 for biopharma.

William Blair's biopharma team shares additional perspectives on the biopharma environment in Q1 2024 and what to expect for the remainder of the year.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Primutec Solutions Group Has Agreed to be Acquired by Trill Impact

    William Blair acted as the exclusive financial advisor to Primutec Solutions Group B.V., owned by Funds advised by DPE Deutsche Private Equity Management and management, in connection with its pending sale to Funds managed by Trill Impact.

    Read more
  • Critical Tariff-Related M&A Due Diligence Questions

    Recent tariff-related disruptions have significantly expanded the scope of M&A due diligence, with buyers now asking target companies an array of questions to assess new trade policy risk.

    Read more
  • Inflexion Raises a Multi-Asset Continuation Fund for Four Assets

    William Blair acted as a financial advisor to Inflexion Buyout V Investments LP, in connection with the successful close of a £2.3 billion multi-asset continuation fund, the Inflexion Continuation Fund I.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures